What Cellmover does

Cellmover AS is a pre-clinical stage Norwegian biotechnology company developing nanobody- and peptide-based therapeutics for cancer immunotherapy. Founded in 2015 and headquartered in the ShareLab incubator at Oslo Science Park, the company has built a library of nanobodies and peptides directed at intracellular targets in T cells and NK cells — proteins that reside inside immune cells and were previously considered "undruggable" by conventional extracellular biologics. Cellmover's "Intracellular Biologics Platform" is designed to access the roughly 61% of the human proteome located intracellularly, with the goal of mediating increased survival and persistence of immune cells within the tumor microenvironment. Its pipeline comprises three named drug candidates — CM101 (in discovery), CM102 (lead optimization), and CM103 (lead optimization) — none of which have yet entered IND-enabling studies or clinical trials.

The company's business model is pre-revenue and centered on advancing its pipeline through preclinical and clinical development, with anticipated future monetization through licensing deals, strategic collaborations, or commercialization of successful therapeutic products with larger pharmaceutical partners. Business development is supported by an external BD Advisor (Eirik Næss-Ulseth). The company is privately held, founder-owned (Marit Inngjerdingen serves as Founder and Chairman), and funded through a mix of non-dilutive grants (Norwegian Research Council, Eurostars) and incubator support (ShareLab membership since May 2024; Aleap membership since October 2025). No institutional venture capital, private equity, or strategic investor ownership has been disclosed. The team consists of six core members including the founder/chairman, CEO, senior scientist, lab engineer, associate scientist, and BD advisor; a CEO transition occurred in November 2025 with Miriam Aarsund Larsen promoted from CSO to CEO.

Name

Cellmover

Legal name

Cellmover AS

Website

https://cellmover.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

Cellmover AS is a pre-clinical Norwegian biotechnology company developing a proprietary library of nanobodies and peptides that target intracellular proteins in T cells and NK cells to enhance immune cell persistence in tumors for cancer immunotherapy.

Ownership category

akta.pro rank

Product category

Cancer Immunotherapy / Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish) (HLAAABAG)

akta.pro secondary industry

NK Cell Therapies (HLAAABAD)

Keywords

• Nanobody therapeutics
• Cancer immunotherapy
• Intracellular biologics
• Preclinical drug development
• Immune cell engineering

Headquarters

HQ city

Oslo

HQ country

Norway

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations

Revenue model

1. Pre-revenue / Pipeline Development: Cellmover is a pre-clinical stage immunotherapy company. As such, the company does not yet generate revenue. Its business model centers on developing a pipeline of nanobody-based therapeutic candidates (CM101, CM102, CM103) through preclinical and clinical stages, with anticipated future revenue derived from licensing deals, partnerships, or commercialization of successful therapeutic products.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Cellmover develops a proprietary library of nanobodies and peptides directed at intracellular targets in T cells and NK cells to enhance cancer immunotherapy. The company is advancing three preclinical drug candidates (CM101, CM102, CM103) targeting intracellular proteins in immune cells to improve survival and persistence within the tumor microenvironment.

Product overview

Cellmover is a pre-clinical stage immunotherapy company developing a platform of nanobody and peptide-based drug candidates targeting intracellular proteins in immune cells. The company's portfolio includes three named drug candidates (CM101, CM102, CM103) in various stages of discovery through pre-clinical development. The technology aims to enhance cancer immunotherapy by improving immune cell survival and persistence within the tumor microenvironment.

Differentiator

Problem solved

Functional benefit

Products and services

• CM101 Lead preclinical drug candidate targeting specific intracellular proteins in T cells and NK cells for cancer immunotherapy. Currently in the discovery stage of preclinical development. Intended for future out-licensing or partnership with pharmaceutical companies.
• CM102 Second preclinical drug candidate targeting specific intracellular proteins in immune cells for cancer immunotherapy. Currently in lead optimization stage. Intended for future out-licensing or partnership with pharmaceutical companies.
• CM103 Third preclinical drug candidate targeting specific intracellular proteins in immune cells for cancer immunotherapy. Currently in lead optimization stage. Intended for future out-licensing or partnership with pharmaceutical companies.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered core.

• AleapcoreStrategic or Co-development Partner · 1 October 2024Aleap is Norway's leading incubator for health and life science start-ups located at Oslo Science Park. Cellmover joined Aleap in October 2024 to gain access to industry experts, mentors, investors, and strategic guidance across regulatory, intellectual property, business development, and clinical operations.
• ShareLabcoreStrategic or Co-development Partner · 1 May 2024ShareLab is a biotech incubator at Oslo Science Park. Cellmover joined ShareLab in May 2024, describing it as a milestone for the company. ShareLab membership enables acceleration of R&D, opens opportunities for collaboration, and supports the company's mission to develop cancer immunotherapies.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Nkarta Therapeutics: Clinical-stage NK cell therapy developer focused on engineered NK cells for oncology. Direct peer because Cellmover targets NK cells (alongside T cells) and aims to enhance NK cell persistence via nanobodies, conceptually adjacent to NKarta's engineered NK platform.
• argenx: Clinical-stage leader in nanobody-based therapeutics (VHH antibody fragments) for immunology and oncology indications. Most directly comparable peer to Cellmover given shared nanobody scaffold focus and ambitions to expand into intracellular and previously undruggable target spaces.
• Crescendo Biologics: Clinical-stage developer of T-cell engagers using a proprietary VH domain platform (T-cell enhancing Humabody). Closely analogous to Cellmover's nanobody-based approach for redirecting and enhancing T-cell function in cancer, sharing both scaffold class and modality.
• Ablynx (Sanofi): Pioneering nanobody platform originally developed by Ablynx and acquired by Sanofi for ~$4.8B. Sets the architectural template for nanobody-based therapeutic development that Cellmover's platform follows and validates the commercial potential of nanobody-based franchises.
• Harpoon Therapeutics (now Merck): Developed T-cell engagers using a proprietary tri-specific T-cell activating construct (TriTAC) platform for solid tumors, acquired by Merck for ~$680M. Comparable peer as another engineered approach to T-cell engagement in oncology that validates pharma appetite for novel T-cell-focused platforms.
• Allogene Therapeutics: Clinical-stage allogeneic CAR-T developer advancing off-the-shelf cell therapies for cancer. Relevant peer given overlapping T-cell oncology focus and shared emphasis on improving persistence and efficacy of engineered immune cells in solid tumors.
• Adaptimmune: Develops engineered T-cell receptor (TCR) therapies for solid tumors. Operates in the same addressable space of enhancing T-cell persistence and efficacy in the tumor microenvironment that Cellmover's intracellular nanobody approach addresses, serving as a benchmark for T-cell-directed oncology therapeutics.

Emerging players

• Compass Therapeutics: Clinical-stage bispecific antibody developer with oncology programs designed to enhance immune cell engagement against tumors. Emerging peer with a complementary engineered-protein approach to T-cell redirection in oncology.

Regional players

• NeoPhore: European (UK/Switzerland) small-molecule immuno-oncology company. Regional emerging peer illustrating the European biotech competitive landscape for cancer immunotherapy developers of similar early-stage scale to Cellmover.

Broad incumbents

• Micromet / blinatumomab (Amgen): Pioneer of BiTE (bispecific T-cell engager) technology, acquired by Amgen for ~$1.2B; blinatumomab is approved for ALL. Broad incumbent showing clinical proof of concept for T-cell-engaging modalities in oncology that informs the commercial context for novel platforms like Cellmover's.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/Cellmove
• Facebookfacebook.com/cellmover
• LinkedInlinkedin.com/company/cellmover-as

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cellmover